NPM1 and acute myeloid leukemia: For NPM1-mutant AML patients, the CR + CRi rate was 100% at 200 mg and 86% at 400 mg, with MRD negativity among the responders of 100% and 80%, respectively; for the KMT2A-rearranged patients, the CR + CRi rates were 90% at 200 mg and 63% at 400 mg, with an MRD negativity rate among the responders of 83% and 100%, respectively [124].